Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

26.93 -0.37 (-1.34%)

Streaming Delayed Price Updated: 11:02 AM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4

March 02, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceu...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell ↗

March 02, 2026

The reason is so compelling that I actually did buy the stock -- and I have no plans to sell.

Via The Motley Fool

Topics Intellectual Property

Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need ↗

March 01, 2026

Don't follow general market sentiment when it comes to these two stocks.

Via The Motley Fool

Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead? ↗

March 01, 2026

Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.

Via The Motley Fool

Topics Intellectual Property

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗

February 27, 2026

Sorry, Teva, it's not you ... it's me.

Via The Motley Fool

Topics Intellectual Property

Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety

February 27, 2026

As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

The Implementation Pivot: How Accenture Defied the ‘SaaS-pocalypse’ with a Massive AI Rebound

February 27, 2026

As of February 27, 2026, the global technology sector is grappling with a profound identity crisis often dubbed the "SaaS-pocalypse." While many software-as-a-service providers have seen their...

Via MarketMinute

Topics Artificial Intelligence Economy

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

February 27, 2026

The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While...

Via MarketMinute

Topics Artificial Intelligence Economy

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Via MarketMinute

Topics Artificial Intelligence ETFs

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

February 27, 2026

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines

February 27, 2026

As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of...

Via Finterra

Topics Economy

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

February 27, 2026

From Pfizer Inc.

Via Business Wire

Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Amneal (AMRX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? ↗

February 27, 2026

Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.

Via Stocktwits

Topics Earnings

2 Reasons to Like ZTS (and 1 Not So Much)

February 26, 2026

Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the...

Via StockStory

Topics Stocks

OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

February 26, 2026

Even amid volatility, Pfizer keeps rewarding shareholders year after year.

Via Barchart.com

Topics Artificial Intelligence

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

Topics Economy Intellectual Property

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

February 26, 2026

As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the...

Via Finterra

Topics Economy

This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

February 26, 2026

Via Benzinga

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025

February 26, 2026

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of...

Via StockStory

NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash ↗

February 26, 2026

Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly.

Via Stocktwits

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

February 25, 2026

The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,...

Via MarketMinute

Topics Intellectual Property

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Via The Motley Fool

Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment ↗

February 25, 2026

Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation.

Via Benzinga

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment ↗

February 25, 2026

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset.

Via Benzinga

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

February 25, 2026

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects

Via Barchart.com

Topics ETFs Intellectual Property World Trade

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

February 24, 2026

From Pfizer Inc.

Via Business Wire

Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗

February 24, 2026

According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.

Via Stocktwits

Topics Artificial Intelligence Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.